Senti Biosciences, Inc. (SNTI)
(Delayed Data from NSDQ)
$3.15 USD
+0.02 (0.56%)
Updated Sep 20, 2024 04:00 PM ET
After-Market: $3.25 +0.10 (3.17%) 7:58 PM ET
3-Hold of 5 3
F Value C Growth F Momentum F VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$3.15 USD
+0.02 (0.56%)
Updated Sep 20, 2024 04:00 PM ET
After-Market: $3.25 +0.10 (3.17%) 7:58 PM ET
3-Hold of 5 3
F Value C Growth F Momentum F VGM
Zacks News
Senti Bio (SNTI) Rises as FDA Clears IND for Cancer Candidate
by Zacks Equity Research
The FDA clears Senti Bio's (SNTI) investigational new drug application for SENTI-202 for the treatment of relapsed/refractory hematologic malignancies, including acute myeloid leukemia. Stock rises.
Senti Biosciences, Inc. (SNTI) Reports Q2 Loss, Misses Revenue Estimates
by Zacks Equity Research
Senti Biosciences, Inc. (SNTI) delivered earnings and revenue surprises of 12.50% and 27.36%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Urogen Pharma (URGN) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Urogen Pharma (URGN) delivered earnings and revenue surprises of 8.85% and 6.23%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Bionano Genomics, Inc. (BNGO) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Bionano Genomics, Inc. (BNGO) delivered earnings and revenue surprises of -37.78% and 6.81%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Sangamo Therapeutics (SGMO) Reports Q2 Loss, Misses Revenue Estimates
by Zacks Equity Research
Sangamo (SGMO) delivered earnings and revenue surprises of -5.71% and 69.39%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
GSK (GSK) Surpasses Q2 Earnings and Revenue Estimates
by Zacks Equity Research
Glaxo (GSK) delivered earnings and revenue surprises of 14.12% and 5.81%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?